Trials / Unknown
UnknownNCT03850314
The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters.
The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters: A Clinical and Ex-vivo Study.
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Prof. Tony hayek MD · Academic / Other
- Sex
- Male
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The current study will test the central hypothesis that Glycine supplementation in humans improves Lipid profile and therefore reduces the risk of Atherosclerosis. Secondary outcomes including Insulin sensitivity and parameters related to Metabolic Syndrome (MetS) will also be measured. Furthermore, a mechanistic study in an ex-vivo model will test the hypothesis that Glycine via its key biosynthetic pathway involving Serine Hydroxymethyltransferase 2 (SHMT2), is athero-protective by inhibiting Sterol regulatory element-binding protein 2 (SREBP2)-mediated cholesterol biosynthesis in murine macrophage-like cell line.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Glycine | Glycine powder to be dissolved in water. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2019-12-01
- Completion
- 2020-06-01
- First posted
- 2019-02-21
- Last updated
- 2019-02-21
Source: ClinicalTrials.gov record NCT03850314. Inclusion in this directory is not an endorsement.